CBD-Based Products Show Promise for Pets With Pain, Seizures, and Skin Problems ↗
Systematic review of 22 studies finds CBD-based products improve pain, seizures, and skin conditions in dogs with no serious side effects, but cat research is minimal.
Browse more cannabis research, findings, methods, and limitations.
Systematic review of 22 studies finds CBD-based products improve pain, seizures, and skin conditions in dogs with no serious side effects, but cat research is minimal.
Low-dose cannabinoid treatment prevented spatial memory loss in rats by indirectly boosting the cholinergic system through cannabinoid receptor activation in cortical regions.
Mouse embryo study discovers that both too much and too little endocannabinoid signaling causes catastrophic membrane ruptures in 40% of migrating brain cells during development.
Human clinical data shows CBD, but not THC, boosts anti-inflammatory lipid production through the 15-LOX pathway, providing molecular evidence for CBD's therapeutic potential.
CB1 receptor blocker caused 27% weight loss in obese mice and improved airway function, identifying the endocannabinoid system as a link between obesity and asthma.
Daily diary study of 40 women finds cannabis use peaks premenstrually, with mood and pain/coping motives interacting differently across menstrual cycle phases.
National survey finds medical cannabis laws increase and perceived penalties decrease teen cannabis use, with legalization weakening the protective effect of social bonds.
CBD reduced brain inflammation, oxidative stress, and cognitive impairment in rats with liver disease-induced brain dysfunction through multiple anti-inflammatory pathways.
Randomized trial finds CBD improves walking speed and reduces pain in MS patients but does not directly reduce spasticity, suggesting CBD may help through alternative mechanisms.
Pilot RCT finds full-spectrum CBD with trace THC reduced alcohol craving in people with AUD, while CBD without THC did not, suggesting the trace THC component matters.
CBD modulates immune function through multiple mechanisms with potential for autoimmune diseases, though most evidence remains preclinical. Nanotechnology may improve delivery.
Controlled study finds CBD/CBDA paste effectively reduces arthritis pain in cats, but nearly half dropped out due to refusal to eat the paste, highlighting a formulation challenge.
Among 540 older adults across the dementia spectrum, moderate cannabis use was not associated with worse cognitive test performance—though problem use may differ.
Meta-analysis of 29 studies finds cannabis use in schizophrenia linked to 40% higher suicide attempt odds and 21% higher suicide death risk.
Systematic review of 8,849 women finds consistent evidence that cannabis use before sex improves orgasm function, though quality evidence is limited.
Experts argue cannabis pain trials measure the wrong things: patients value psychological coping, sleep, and opioid reduction more than direct pain relief.
Two-year study finds 40% of cannabis-using chronic pain patients at high CUD risk with worse mental health, but pain outcomes do not worsen compared to non-users.
Review finds cannabis concentrate vaping produces significant toxic byproducts and some products contain hazardous additives, as research lags far behind market growth.
The most comprehensive review to date (89 studies) finds prenatal cannabis exposure harmful for fetal growth and development, concluding cannabis should be avoided during pregnancy.
A small RCT found that topical CBD plus myrcene gel significantly reduced pain during sex for women with vestibulodynia compared to placebo over 60 days.
A narrative review of cannabis effects across the lifespan found that prenatal and adolescent exposure carries the highest neurological risk, while cannabis use among older adults is rising fastest with the least risk awareness.
A review warns that 30 years of rising methamphetamine and high-potency cannabis use have fueled a growing wave of drug-induced psychosis, with up to half of cases progressing to schizophrenia.
A population-based Canadian study found cannabis-related hospitalizations dropped 34% among youth below the legal purchase age after legalization, while continuing to rise among adults above it.
An Ontario study of 11.6 million people found that individuals hospitalized for cannabis use disorder were nearly 3 times more likely to die within 5 years, with especially high risks for suicide and trauma.
An Ontario study of 13.6 million people found the share of schizophrenia cases linked to cannabis use disorder nearly tripled from 3.7% to 10.3% during a period of cannabis policy liberalization, reaching 18.9% among young men.
An Ontario study of 6.1 million adults over 45 found that those with emergency visits for cannabis use had 1.72x higher dementia risk than the general population, though lower risk than those with alcohol-related visits.
A nationally representative study found cannabis use among young adults in the country of Georgia barely changed four years after legalization, though the drug became easier to obtain and first use shifted to older ages.
A mixed-method study found that only 36% of Georgian primary care physicians were familiar with cannabis laws, and 88% had never used diagnostic criteria for cannabis use disorders, citing time constraints and stigma as key barriers.
An ABCD Study analysis of nearly 10,000 children found that prenatal exposure to both cannabis and tobacco was linked to more externalizing behavior problems at ages 9-11 than exposure to either substance alone.
An ABCD Study analysis of 7,691 adolescents found that more social media time at age 12 predicted cannabis experimentation by age 14, with beliefs about cannabis effects mediating about a third of the relationship.
An ABCD Study of nearly 10,000 adolescents found that cyberbullying victims were 4.65 times more likely to try cannabis within the next year, alongside increased risks for depression and suicidal behavior.
An ABCD Study of 8,006 early teens found that social media, texting, and video chatting were linked to cannabis and other substance experimentation one year later, while TV, video games, and passive screen use were not.
A systematic review of 18 studies found preclinical promise for cannabinoids in supporting healthy aging, but noted that human evidence remains too sparse to draw definitive conclusions.
An analysis of over 624,000 cannabis products on Leafly and Weedmaps found more than 26,000 listings making health benefit claims, with mood disorders, pain, and sleep being the most common.
Sixteen Iranian psychiatrists identified reduced stigma and patient empowerment as potential benefits of demedicalization of cannabis use disorder, while warning of treatment challenges and normalization risks.
A crossover RCT of 20 healthy adults found that low-dose THC:CBD oils (1:1 and 1:16 ratios) did not cause daytime sleepiness or change night-time sleep compared to placebo.
A study of 637 breast milk samples found that those with detectable cannabis metabolites had higher protein and 11% lower fat content, with no changes in calories or carbohydrates.
A 12-state US study found illicit cannabis persists alongside legal markets, hemp-derived THC is growing rapidly in regulatory gaps, and THC products dominate 90%+ of all cannabis market value.
CBD reduced involuntary movements caused by Parkinson's medication in rats without diminishing the drug's motor benefits, working through CB1, PPARy receptors, and endocannabinoid pathways.
A legal analysis traces Indonesian cannabis use from the 14th century to modern Constitutional Court battles, arguing that punitive policies conflict with human rights and centuries of cultural practice.
A study of 240 Iranians found that a genetic variant in the cannabinoid CB2 receptor gene was associated with more than 2.5 times the risk of developing rheumatoid arthritis.
Chronic CBD from weaning reversed anxiety, brain molecular changes, gut microbiota dysbiosis, and increased alcohol motivation in mice with fetal alcohol exposure, with effects varying by sex.
A practical clinical guide to prescribing pharmaceutical CBD for drug-resistant epilepsy—covering dosing strategies, drug interactions, and the 'start low, go slow' approach.
A study of 93,743 US adults found that cannabis use mediated a larger share of the link between depression, pain, and suicidal behavior in women than in men.
A study of 152,930 US adults found that using cannabis and opioids together was associated with a smaller-than-expected increase in suicidal behaviors, particularly in women.
Recreational marijuana laws were linked to an increase of 0.68 suicide deaths per 100,000 overall, but early-adopting states saw decreases while later-adopting states drove the increase.
A Quebec study found that higher cannabis sales were linked to 12% more drug-related and 12% more alcohol-related traffic crashes across five cities, with Montreal showing 87-93% increases.
THC altered hippocampal neurotransmission in female rats, but the direction of effects depended on whether estrogen was present, revealing a complex hormone-cannabinoid interaction in the brain.
A review found consistent preclinical evidence that endocannabinoid modulation can improve PTSD-related behaviors, but human research remains mixed and insufficient to support clinical cannabinoid therapy for PTSD.
Interviews with 20 young adults found stronger motivation to quit nicotine vaping than cannabis vaping, with addiction, mental health coping, and identity as key barriers, and health concerns as the main facilitator.